MYD88 Gene Mutation
3 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL (NCT05233033) | Kymera Therapeutics, Inc. | 2022-06-13 |
| Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies (NCT04994626) | Chinese Academy of Medical Sciences | 2021-10-01 |
| Ibrutinib + Venetoclax in Untreated WM (NCT04273139) | Dana-Farber Cancer Institute | 2020-07-09 |
Track MYD88 Gene Mutation automatically
Every clearance here is in the API, with alerts when new ones post.